Literature DB >> 33349261

Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection.

Leonardo Miscio1, Antonio Olivieri2, Francesco Labonia3, Gianfranco De Feo3, Paolo Chiodini4, Giuseppe Portella5, Luigi Atripaldi6, Roberto Parrella6, Rodolfo Conenna6, Franco Maria Buonaguro3, Ernesta Cavalcanti3, Paolo Ascierto3, Gerardo Botti3, Attilio Bianchi3.   

Abstract

BACKGROUND: The easy access to a quick diagnosis of coronavirus disease 2019 (COVID-19) is a key point to improve the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to contain its spread. Up to now, laboratory real-time PCR is the standard of care, but requires a fully equipped laboratory and significant infrastructure. Consequently, new diagnostic tools are required.
METHODS: In the present work, the diagnostic accuracy of the point-of-care rapid test "bKIT Virus Finder COVID-19" (Hyris Ltd) is evaluated by a retrospective and a prospective analysis on SARS CoV-2 samples previously assessed with an FDA "authorized for the emergency use-EUA" reference method. Descriptive statistics were used for the present study.
RESULTS: Results obtained with the Hyris Kit are the same as that of standard laboratory-based real time PCR methods for all the analyzed samples. In addition, the Hyris Kit provides the test results in less than 2 h, a significantly shorter time compared to the reference methods, without the need of a fully equipped laboratory.
CONCLUSIONS: To conclude, the Hyris kit represents a promising tool to improve the health surveillance and to increase the capacity of SARS-CoV-2 testing.

Entities:  

Keywords:  COVID-19; Health surveillance; Point-of-care rapid test; SARS-CoV-2

Mesh:

Year:  2020        PMID: 33349261      PMCID: PMC7752099          DOI: 10.1186/s12967-020-02651-y

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


  13 in total

Review 1.  Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2.

Authors:  Nadin Younes; Duaa W Al-Sadeq; Hadeel Al-Jighefee; Salma Younes; Ola Al-Jamal; Hanin I Daas; Hadi M Yassine; Gheyath K Nasrallah
Journal:  Viruses       Date:  2020-05-26       Impact factor: 5.048

Review 2.  Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2).

Authors:  Roshan J D'Cruz; Arthur W Currier; Valerie B Sampson
Journal:  Front Cell Dev Biol       Date:  2020-06-04

3.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

4.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.

Authors: 
Journal:  Nat Microbiol       Date:  2020-03-02       Impact factor: 17.745

5.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.

Authors:  Victor M Corman; Olfert Landt; Marco Kaiser; Richard Molenkamp; Adam Meijer; Daniel Kw Chu; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Marie Luisa Schmidt; Daphne Gjc Mulders; Bart L Haagmans; Bas van der Veer; Sharon van den Brink; Lisa Wijsman; Gabriel Goderski; Jean-Louis Romette; Joanna Ellis; Maria Zambon; Malik Peiris; Herman Goossens; Chantal Reusken; Marion Pg Koopmans; Christian Drosten
Journal:  Euro Surveill       Date:  2020-01

6.  Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.

Authors:  Fabrizio Cantini; Delia Goletti; Linda Petrone; Saied Najafi Fard; Laura Niccoli; Rosario Foti
Journal:  Drugs       Date:  2020-12       Impact factor: 9.546

7.  Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.

Authors:  Jacqueline Dinnes; Jonathan J Deeks; Ada Adriano; Sarah Berhane; Clare Davenport; Sabine Dittrich; Devy Emperador; Yemisi Takwoingi; Jane Cunningham; Sophie Beese; Janine Dretzke; Lavinia Ferrante di Ruffano; Isobel M Harris; Malcolm J Price; Sian Taylor-Phillips; Lotty Hooft; Mariska Mg Leeflang; René Spijker; Ann Van den Bruel
Journal:  Cochrane Database Syst Rev       Date:  2020-08-26

8.  Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020.

Authors:  Rui Liu; Huan Han; Fang Liu; Zhihua Lv; Kailang Wu; Yingle Liu; Yong Feng; Chengliang Zhu
Journal:  Clin Chim Acta       Date:  2020-03-07       Impact factor: 3.786

9.  Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.

Authors:  M Alejandra Tortorici; Martina Beltramello; Florian A Lempp; Dora Pinto; Ha V Dang; Laura E Rosen; Matthew McCallum; John Bowen; Andrea Minola; Stefano Jaconi; Fabrizia Zatta; Anna De Marco; Barbara Guarino; Siro Bianchi; Elvin J Lauron; Heather Tucker; Jiayi Zhou; Alessia Peter; Colin Havenar-Daughton; Jason A Wojcechowskyj; James Brett Case; Rita E Chen; Hannah Kaiser; Martin Montiel-Ruiz; Marcel Meury; Nadine Czudnochowski; Roberto Spreafico; Josh Dillen; Cindy Ng; Nicole Sprugasci; Katja Culap; Fabio Benigni; Rana Abdelnabi; Shi-Yan Caroline Foo; Michael A Schmid; Elisabetta Cameroni; Agostino Riva; Arianna Gabrieli; Massimo Galli; Matteo S Pizzuto; Johan Neyts; Michael S Diamond; Herbert W Virgin; Gyorgy Snell; Davide Corti; Katja Fink; David Veesler
Journal:  Science       Date:  2020-09-24       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.